Rialto Wealth Management LLC Invests $839,000 in Mesoblast Limited $MESO

Rialto Wealth Management LLC acquired a new position in shares of Mesoblast Limited (NASDAQ:MESO) during the fourth quarter, HoldingsChannel reports. The firm acquired 46,500 shares of the company’s stock, valued at approximately $839,000.

Several other institutional investors have also added to or reduced their stakes in MESO. Brooklyn Investment Group bought a new position in Mesoblast during the 3rd quarter worth about $655,000. Squarepoint Ops LLC boosted its position in shares of Mesoblast by 116.8% during the third quarter. Squarepoint Ops LLC now owns 31,656 shares of the company’s stock worth $510,000 after buying an additional 17,053 shares during the period. Creative Planning bought a new position in shares of Mesoblast during the second quarter worth about $141,000. Quadrant Capital Group LLC acquired a new stake in Mesoblast in the 3rd quarter valued at approximately $113,000. Finally, Raymond James Financial Inc. bought a new stake in Mesoblast in the 2nd quarter valued at approximately $86,000. 1.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Mesoblast presently has an average rating of “Moderate Buy”.

Mesoblast Stock Down 2.4%

NASDAQ:MESO opened at $14.02 on Tuesday. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -15.93 and a beta of 2.17. The company has a quick ratio of 1.41, a current ratio of 1.58 and a debt-to-equity ratio of 0.10. Mesoblast Limited has a twelve month low of $9.61 and a twelve month high of $21.50. The stock’s 50 day moving average price is $16.54 and its two-hundred day moving average price is $16.90.

Mesoblast (NASDAQ:MESO) last released its earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $25.67 million for the quarter. Equities research analysts expect that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.

Mesoblast Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.